Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: results from the randomised ARTFORCE PET-boost trial
Cooke, S. A. Belderbos, J. S. A. Reymen, B. Lambrecht, M. Fredberg Persson, G. Dieleman, E. M. T. van Diessen, J. N. A. Sonke, J. J. de Ruysscher, D.
Cooke, S. A.
Belderbos, J. S. A.
Reymen, B.
Lambrecht, M.
Fredberg Persson, G.
Dieleman, E. M. T.
van Diessen, J. N. A.
Sonke, J. J.
de Ruysscher, D.
Citations
Altmetric:
Abstract
BACKGROUND AND PURPOSE: The ultimate challenge in dose-escalation trials lies in finding the balance between benefit and toxicity. We examined patient-reported outcomes (PROs), including health-related quality of life (HRQoL) in patients with locally advanced non-small cell lung cancer (LA-NSCLC), treated with dose-escalated radiotherapy. MATERIALS AND METHODS: The international, randomised, phase 2 ARTFORCE PET-Boost study (NCT01024829) aimed to improve 1-year freedom from local failure rates in patients with stage II-III NSCLC, with a ≥ 4 cm primary tumour. Treatment consisted of an individualised, escalated fraction dose, either to the primary tumour as a whole or to its most FDG-avid subvolume (24 x 3.0-5.4 Gy). Patients received sequential or concurrent chemoradiotherapy, or radiotherapy only. Patients were asked to complete the EORTC QLQ-C30, QLQ-LC13, and the EuroQol-5D at eight timepoints. We assessed the effect of dose-escalation on C30 sum score through mixed-modelling and evaluated clinically meaningful changes for all outcomes. RESULTS: Between Apr-2010 and Sep-2017, 107 patients were randomised; 102 were included in the current analysis. Compliance rates: baseline 86.3%, 3-months 85.3%, 12-months 80.3%; lowest during radiation treatment 35.0%. A linear mixed-effect (LME) model revealed no significant change in overall HRQoL over time, and no significant difference between the two treatment groups. Physical functioning showed a gradual decline in both groups during treatment and at 18-months follow-up, while clinically meaningful worsening of dyspnoea was seen mainly at 3- and 6-months. CONCLUSION: In patients with LA-NSCLC treated with two dose-escalation strategies, the average patient-reported HRQoL remained stable in both groups, despite frequent patient-reported symptoms, including dyspnoea, dysphagia, and fatigue.
Description
Date
2024
Publisher
Collections
Keywords
Type
Article
Citation
Cooke SA, Belderbos JSA, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, et al. Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2024 Jul;196:110312. PubMed PMID: 38663582. Epub 2024/04/26. eng.